Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.2 USD | -3.06% | -9.00% | -14.68% |
05-09 | UBS Adjusts Price Target on REGENXBIO to $39 From $43, Maintains Buy Rating | MT |
05-08 | Transcript : REGENXBIO Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.68% | 769M | |
+3.24% | 108B | |
+11.19% | 104B | |
+1.28% | 22.33B | |
-12.73% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-9.62% | 17.64B | |
+4.24% | 14.05B | |
+34.97% | 12.51B |
- Stock Market
- Equities
- RGNX Stock
- News REGENXBIO Inc.
- RBC Upgrades REGENXBIO to Outperform From Sector Perform, Lifts Price Target to $35 From $20, 'Impressed by Recent Execution,' Keeps Speculative Risk